How the cell-division protein MAD2 changes shape as it's made on human ribosomes

Co-Translational Folding of Metamorphic Proteins: Assessing Structure-Function Transitions of the Mitotic Checkpoint Protein MAD2 on the Human Ribosome Surface and in the Presence of Folding Effectors

NIH-funded research Stanford University · NIH-11179498

This project looks at how a key cell-division protein called MAD2 folds into different shapes while it's being made, which matters for preventing chromosome errors that can lead to cancer.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionStanford University NIH-funded
Lab location1 site (Stanford, United States)
Project IDNIH-11179498 on NIH RePORTER

What this research studies

From a patient's perspective, researchers are watching a single MAD2 molecule as it is produced on a human ribosome to see whether it adopts one shape or switches between shapes during synthesis. They use a novel single-human-ribosome translation assay with optical tweezers to follow the folding path in real time. The team will also test how cellular helpers called chaperones and other folding effectors change MAD2's folding choices. The goal is to understand the molecular steps that can lead to proper or faulty mitotic checkpoint function, which is linked to chromosome instability and cancer.

Who could benefit from this research

Good fit: People with cancers characterized by chromosome instability, or patients willing to donate tumor or blood samples for related laboratory research, would be the most relevant participants to this line of work.

Not a fit: Patients without cancer or with cancers unrelated to mitotic checkpoint dysfunction are unlikely to receive direct benefit from this basic laboratory research.

Why it matters

Potential benefit: If successful, this work could reveal how MAD2 misfolding contributes to chromosome instability and point to new targets or strategies to prevent or treat cancers tied to faulty cell division.

How similar studies have performed: Previous protein-folding and mitotic-checkpoint studies have advanced understanding, but using single-human-ribosome optical tweezers to watch MAD2 fold in real time is a novel and largely untested approach.

Where this research is happening

Stanford, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions CancerousCancers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.